Create Free Account

By creating account you will get access to hot stocks & personalised emails

Eli Lilly and Company

Healthcare US LLY

758.87USD
-5.84(0.76%)

Last update at 2024-12-19T18:57:00Z

Day Range

752.39772.97
LowHigh

52 Week Range

307.17628.81
LowHigh

Fundamentals

  • Previous Close 764.71
  • Market Cap541475.24M
  • Volume1819887
  • P/E Ratio103.14
  • Dividend Yield0.91%
  • EBITDA11316.30M
  • Revenue TTM32072.50M
  • Revenue Per Share TTM35.62
  • Gross Profit TTM 21911.60M
  • Diluted EPS TTM5.53

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 6806.40M 6155.50M 7229.90M 5265.90M 3680.10M
Minority interest - - 183.60M 92.20M 1080.40M
Net income 6244.80M 5581.70M 6193.70M 4637.90M 3232.00M
Selling general administrative 6440.40M 6431.60M 6121.20M 6213.80M 5975.10M
Selling and marketing expenses - - - 6213.80M 5975.10M
Gross profit 21911.60M 21005.60M 19056.50M 17598.30M 16811.60M
Reconciled depreciation 1522.50M 1547.60M 1323.90M 1232.60M 1609.00M
Ebit 7127.30M 6357.10M 6058.00M 4974.30M 8036.10M
Ebitda 9433.50M 8739.10M 7641.20M 6604.70M 9645.10M
Depreciation and amortization 2306.20M 2382.00M 1583.20M 1630.40M 1609.00M
Non operating income net other -320.90000M - - 291.60M 74.80M
Operating income 7127.30M 6357.10M 6058.00M 4974.30M 6186.80M
Other operating expenses 20261.00M 20770.30M 17690.20M 16530.00M 15708.00M
Interest expense 331.60M 339.80M 359.60M 400.60M 272.10M
Tax provision 561.60M 573.80M 1036.20M 628.00M 563.70M
Interest income 268.80M 314.40M 326.60M 80.40M 161.30M
Net interest income -268.80000M -314.40000M -326.60000M -320.20000M -110.80000M
Extraordinary items - 0.00000M 0.00000M 3680.50M -93.90000M
Non recurring 244.60M - - 815.20M 2465.90M
Other items - - - - -
Income tax expense 561.60M 573.80M 1036.20M 628.00M 529.50M
Total revenue 28541.40M 28318.40M 24539.80M 22319.50M 21493.30M
Total operating expenses 13631.20M 13457.50M 12206.90M 11808.80M 11026.30M
Cost of revenue 6629.80M 7312.80M 5483.30M 4721.20M 4681.70M
Total other income expense net -320.90000M -201.60000M 1171.90M 291.60M -2105.20000M
Discontinued operations - - - 3680.50M 81.40M
Net income from continuing ops 6244.80M 5581.70M 6193.70M 4637.90M 3232.00M
Net income applicable to common shares 6244.80M 5581.70M 6193.70M 8318.40M 3232.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 49489.80M 48806.00M 46633.10M 39286.10M 43908.40M
Intangible assets 7206.60M 7691.90M 7450.00M 6618.00M 1068.00M
Earning assets - - - - -
Other current assets 2954.10M 2530.60M 2871.50M 2538.90M 2146.50M
Total liab 38714.40M 39651.20M 40807.90M 36587.00M 32999.30M
Total stockholder equity 10649.80M 8979.20M 5641.60M 2606.90M 9828.70M
Deferred long term liab 87.30M - - 2187.50M -
Other current liab 13706.50M 3027.50M 2750.30M 2189.40M 9174.80M
Common stock 594.10M 596.30M 598.20M 598.80M 661.00M
Capital stock 594.10M 596.30M 598.20M 598.80M 661.00M
Retained earnings 10042.60M 8958.50M 7830.20M 4920.40M 11395.90M
Other liab 6130.40M 8674.20M 11029.00M 10481.40M 11870.00M
Good will 4073.00M 3892.00M 3766.50M 3679.40M 1366.60M
Other assets 7129.90M 6380.00M 9274.00M 4748.30M 10910.00M
Cash 2067.00M 3818.50M 3657.10M 2337.50M 7320.70M
Cash and equivalents 2067.00M 3818.50M 3657.10M 2337.50M 7320.70M
Total current liabilities 17138.20M 15052.70M 12481.60M 11775.20M 11888.10M
Current deferred revenue - 8816.30M 8115.90M 6681.20M 404.00M
Net debt 14171.60M 13066.20M 12938.20M 13466.40M 2977.90M
Short term debt 1501.10M 1538.30M 8.70M 1499.30M 1102.20M
Short long term debt 1501.10M 1538.30M 8.70M 1499.30M 1131.20M
Short long term debt total 16238.60M 16884.70M 16595.30M 15803.90M 10298.60M
Other stockholder equity 3857.70M 3767.50M 3709.60M 3611.30M 3501.00M
Property plant equipment 10144.00M 8985.10M 8681.90M 7872.90M 8919.50M
Total current assets 18034.50M 18452.40M 17462.10M 13709.60M 20549.60M
Long term investments 2901.80M 3212.60M 2966.80M 1962.40M 2020.70M
Net tangible assets -629.80000M -4014.80000M -5574.90000M -7690.50000M 1960.20M
Short term investments 144.80M 90.10M 24.20M 101.00M 88.20M
Net receivables 8558.90M 8127.20M 6929.00M 5541.50M 5776.80M
Long term debt 14737.50M 15346.40M 16586.60M 13817.90M 11639.70M
Inventory 4309.70M 3886.00M 3980.30M 3190.70M 3098.10M
Accounts payable 1930.60M 1670.60M 1606.70M 1405.30M 1207.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 125.60M - - 92.20M 1080.40M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3844.60000M -4343.10000M -6496.40000M -6523.60000M -5729.20000M
Additional paid in capital - - - - -
Common stock total equity 594.10M - 598.20M 598.80M 661.00M
Preferred stock total equity - - - - -
Retained earnings total equity 10042.60M - - 4920.40M 11395.90M
Treasury stock - -52.70000M -55.70000M -60.80000M -69.40000M
Accumulated amortization - - - - -
Non currrent assets other 4337.00M 4082.70M 3475.40M 2339.10M 8309.00M
Deferred long term asset charges - - - - -
Non current assets total 31455.30M 30353.60M 29171.00M 25576.50M 23358.80M
Capital lease obligations - - - 486.70M -
Long term debt total 14737.50M 15346.40M 16586.60M 13817.90M 11639.70M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -244.00000M -166.00000M 516.70M 456.20M 5111.90M
Change to liabilities 1678.30M -664.10000M 1271.30M -699.00000M -409.80000M
Total cashflows from investing activities -3261.60000M -2762.30000M -2258.90000M -8082.90000M 1906.00M
Net borrowings -62.00000M 501.40M 291.60M 4685.40M -729.30000M
Total cash from financing activities -5406.70000M -4131.30000M -3137.10000M -2324.50000M -5904.90000M
Change to operating activities -793.50000M 1515.40M -457.10000M -602.30000M -980.00000M
Net income 6244.80M 5581.70M 6193.70M 8318.40M 3232.00M
Change in cash -1751.50000M 161.40M 1319.60M -5660.70000M 1462.00M
Begin period cash flow 3818.50M 3657.10M 2337.50M 7998.20M 6536.20M
End period cash flow 2067.00M 3818.50M 3657.10M 2337.50M 7998.20M
Total cash from operating activities 7084.40M 7260.70M 6499.60M 4836.60M 5524.50M
Issuance of capital stock - - - - 1659.70M
Depreciation 1522.50M 1547.60M 1323.90M 1232.60M 1609.00M
Other cashflows from investing activities -1163.30000M 24.30M 102.80M -7505.20000M -1995.30000M
Dividends paid -3535.80000M -3086.80000M -2687.10000M -2409.80000M 2311.80M
Change to inventory -599.70000M -235.90000M -533.40000M -258.70000M 7.80M
Change to account receivables -299.60000M -1278.30000M -1350.00000M -127.20000M -10763.50000M
Sale purchase of stock -1500.00000M -1250.00000M -500.00000M -4400.00000M -4150.70000M
Other cashflows from financing activities 1189.10M -295.90000M -241.60000M -200.10000M -93.00000M
Change to netincome -668.40000M 1154.00M -270.60000M 653.30M 3062.20M
Capital expenditures 2484.00M 1873.20M 2029.10M 1353.50M 3018.20M
Change receivables -299.60000M - - -127.20000M -996.70000M
Cash flows other operating -793.50000M - - -602.30000M -980.00000M
Exchange rate changes - - - -89.90000M -63.60000M
Cash and cash equivalents changes -1583.90000M - - -5660.70000M 1462.00M
Change in working capital -14.50000M -1022.60000M -747.40000M -1687.20000M -2378.70000M
Stock based compensation 371.10M 342.80M 308.10M 312.40M 279.50M
Other non cash items 1145.70M 1613.50M -444.20000M -3402.00000M 2455.90M
Free cash flow 4600.40M 5387.50M 4470.50M 3483.10M 2506.30M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LLY
Eli Lilly and Company		 -5.84 0.76% 758.87 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson		 -0.09 0.06% 144.66 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 0.02 0.01% 173.04 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 1.11 1.13% 99.45 59.83 12.33 4.50 6.47 4.94 23.79
AZN
AstraZeneca PLC ADR		 0.03 0.04% 64.67 38.69 16.31 4.67 5.46 5.20 17.74

Reports Covered

Stock Research & News

View All

Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Lilly Corporate Center, Indianapolis, IN, United States, 46285

Key Executives

Name Title Year Born
Mr. David A. Ricks Chairman, CEO & Pres 1968
Ms. Anat Ashkenazi Sr. VP & CFO 1972
Dr. Daniel M. Skovronsky M.D., Ph.D. Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs 1974
Mr. Diogo Rau Sr. VP & Chief Information and Digital Officer NA
Mr. Jacob S. Van Naarden Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology 1985
Mr. Donald A. Zakrowski Chief Accounting Officer & VP of Fin. NA
Mr. Martin Bott MIBS VP of Fin. & Special Projects 1963
Ms. Anat Hakim J.D. Sr. VP, Gen. Counsel & Sec. 1969
Mr. Alonzo Weems Sr. VP and Chief Ethics & Compliance Officer NA
Ms. Leigh Ann Pusey Sr. VP of Corp. Affairs & Communications 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.